Email d.o.warmerdam@amc.uva.nl to get your message/paper/link posted in the CRISPR Platform news section.
CRISPR seminar
Tuesday, June 4th 2019
Amstelzaal, VUmc, 12:45-17:15
Topics
Basics of CRISPR, CRISPR in mice, CRISPR screens, CRISPR mediated gene activation, CRISPR in organoids CRISPR Knock-in, CRISPR platform Amsterdam UMC
Speakers
Rob Wolthuis, Klaas de Lint, Maarten Bebelman Vincent Christoffels, Johan van Nes, Sanne van Neerven
Keynote speaker
Daniël Warmerdam
For more information and registration please contact:
artecresearch@gmail.com
Chinese researcher He
Jiankui announced he has engineered HIV resistance in a pair of human embryos
using CRISPR: https://www.technologyreview.com/s/612458/exclusive-chinese-scientists-are-creating-crispr-babies
The study, made publicly through
Youtube, raised worldwide ethical concerns. Dutch Scientist including Amsterdam
UMC researcher Sjoerd Repping responded: https://www.nrc.nl/nieuws/2018/11/28/vijf-vragen-over-genetisch-gemanipuleerde-babys-a2779834, as well as Jeantine Lunshof, a leading Dutch ethicist on this
topic: https://www.washingtonpost.com/news/theworldpost/wp/2017/12/12/bioethics/?noredirect=on&utm_term=.4cc384b3f3cd
Amsterdam UMC researchers Rubina Baglio and Michiel Pegtel together with Daniël Warmerdam from the CRISPR Platform have received a grant from the Cancer Center Amsterdam to further develop a new delivery method for CRISPR/Cas in cells and tissues for the potential application in the treatment of cancer.
Instability in the highly repetitive ribosomal DNA could have consequences for the development of neurodegeneration and cancer.
CRISPR Platform researchers Daniël Warmerdam and Rob Wolthuis describe how CRISPR can help to clarify if and how ribosomal DNA instability will impact on human health: https://link.springer.com/article/10.1007%2Fs10577-018-9594-z
In Nederlands Tijdschrift voor Geneeskunde, Henri van de Vrugt, Martina Cornel and Rob Wolthuis discuss the potential applications of CRISPR in the clinic: https://www.ntvg.nl/artikelen/crisprcas-techniek-om-dna-fouten-te-repareren
In C2W, Daniël Warmerdam from the CRISPR Platform comments on CRISPR off-targets:
https://www.c2w.nl/achtergrond/knipt-crispr-cas-kriskras/item19861
John van der Oost, professor of Microbiology at the University of Wageningen, is one of the founders of CRISPR/Cas system. He has made important discoveries on how CRISPR/Cas contributes to bacterial immunity.
Using a variant of Cas9 called Cpf1/Cas12a and the RNA targeting enzyme Cas13a researchers have recently published several methods (1, 2, 3, 4) that allow easy, rapid and highly sensitive detection of various viruses in blood. However, CRISPR diagnostics can be used for various applications, including genotyping and might also be used for early detection of cancer.